In the DEVOTE safety outcomes study, Tresiba U-100 demonstrated no increased risk of major adverse cardiovascular events (MACE) vs Lantus (insulin glargine) U-100 for adults with T2D and ASCVD. The secondary confirmatory endpoint in the DEVOTE study demonstrated significantly lower rates of severe hypoglycemic events as a side effect of Tresiba U-100 vs Lantus (insulin glargine) U-100.